We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more

Pp6.0

Phenylpiracetam Research

Mostly mechanism / observationalModerate safety

5 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Phenylpiracetam studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2010–2025 with a typical study size of 549 participants.

Based on 5 studies · 1 meta-analysis · 549 total participants

Confidence

Moderate

What the studies found

1helped· 4 more without graded effect data

By outcome

Cognitive functionEnhances memory encoding and retrieval in nootropic doses · 1-2 weeks
Mostly mechanism / observational5 studies
Energy & fatigueClean stimulant-like energy · 30-60 minutes
Mostly mechanism / observational3 studies
Neuroprotection & brain aging
Too few graded studies2 studies
Therapeutic & clinical
Too few graded studies1 study
Anxiety & stress
Too few graded studies1 study
Safety profile
Too few graded studies1 study

By the numbers

Pulled from 5 studies with measurable effects

Likely real effects

100%

across studies

People studied

549

typical study: 549 people

Strongest designs

1 pooled, 0 randomised

Showed benefit

100%

1/1 studies

How long studies ran

1–4 weeks

Populations Studied

General population2

Patients with asthenic syndrome1

Patients with cerebral ischemia, neurodegenerative pathologies, epilepsy, asthenia, and mental disorders1

Patients with asthenic conditions and cognitive dysfunction1

Active research area

4 studies in the last 5 years · Latest meta-analysis: 2025

201020172025

1Asthenic syndrome reduction (MFI-20 scale)Meta-Analysisn=549 · large study2025

Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.

Devlikamova FI et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2025)

Noticeable benefit

← WorseNo effectBetter →

Likely real

The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1-53.7).
In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85-23.85 points) (p<0.0001).
During treatment with fonturacetam, the frequency of side effects averaged 5.5%.

View source

2Systematic Review2024

The adaptogenic properties and mitochondrial protective effect of PP are considered, assessments of the possible effect of PP on neurotransmitter systems, regulation of carbohydrate and fat metabolism with the prospects for the use of PP in patients with metabolic syndrome.

Gromova OA et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)

Phenylpiracetam (PP) is a nootropic drug with additional pharmacological effects, including anxiolytic, antiasthenic, antidepressant, anti-inflammatory and anticonvulsant effects.
The paper presents the results of an analysis of experimental and clinical studies, which indicate the prospects for the use of PP in cerebral ischemia, neurodegenerative pathologies, epilepsy, asthenia, and mental disorders.
The adaptogenic properties and mitochondrial protective effect of PP are considered, assessments of the possible effect of PP on neurotransmitter systems, regulation of carbohydrate and fat metabolism with the prospects for the use of PP in patients with metabolic syndrome.

View source

3Cognitive enhancementSystematic ReviewCited 2×2022

Phenylpiracetam demonstrates both cognitive-enhancing and cold-tolerance enhancing effects in clinical trials.

Froestl W et al. · Pharmacological Reports (2022)

Enhanced cognitive performance and psychomotor function in controlled trials
Unique cold-resistance and physical endurance properties among racetams
Banned by WADA due to performance-enhancing effects

View source

4Treatment of asthenic conditions with cognitive dysfunctionObservationalCited 2×2023

We discuss the rationale that for treatment of asthenic conditions accompanied by cognitive dysfunction it is justified to use combination therapy - fonturacetam and a preparation containing nicotinoyl-GABA and Ginkgo Biloba.

Titova NV et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)

Fatigue can also be classified by neuromuscular and/or cognitive and mental fatigue.
The article discusses the neuroanatomical basis and focuses on the neurocognitive theory of pathological fatigue.
In addition the relationship between mental stress, fatigue and cognitive impairments such as subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are also discussed.

View source

5Cognitive function and physical performanceReview2010

Phenylpiracetam improved cognitive function and physical performance in clinical trials.

Malykh AG et al. · Drugs (2010)

Enhanced cognitive function
Improved physical performance
Increased cold tolerance

View source

View in Research Library

Phenylpiracetam Research

Mostly mechanism / observational

By the numbers

[Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis]

[Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use]

Racetam Family of Nootropics: Comprehensive Review of Pharmacology and Clinical Applications

[Asthenia, mental fatigue and cognitive dysfunction]

Phenylpiracetam in cognitive and physical enhancement